Remi Health, a Berlin-based Diagnostics-as-a-Service platform, has raised a €3 million seed round bringing total funding to €5 million. The round was led by IBB Ventures with participation from Catalpa Ventures, MSD Global Health Innovation Fund, and existing pre-seed angels.
Remi Health provides the infrastructure layer that enables payers, digital health companies, pharma, and longevity programs to embed diagnostic testing into patient journeys across European markets – handling collection, logistics, lab connectivity, medical oversight, and country-specific regulatory compliance through a single integration. The company has processed over 1 million diagnostic tests since launch and is working with several major healthcare payers and partners across Europe.
“Decentralised care only works if diagnostics are accessible, trusted, and seamlessly embedded,” said co-CEO and co-founder Anthony Bielenstein. “We remove complexity, so our partners can focus on product innovation, care models, and post-result patient journeys.”
While not women’s health-specific, the platform is relevant infrastructure for the growing number of femtech companies offering at-home diagnostics – from hormone panels and fertility testing to vaginal microbiome analysis and menstrual blood-based screening. Scaling those programs across multiple European markets currently requires navigating fragmented regulatory and laboratory landscapes, which is the problem Remi Health is designed to solve.
The funding will support expansion of the company’s cross-border laboratory network, broader European coverage, and decentralized collection methods including at-home, on-site, and partner collection models. Remi Health is targeting 100 million diagnostic tests processed by 2030.
